SPRI biosensors for quantitative determination of matrix metalloproteinase-2

Abstract

The aim of this study was to develop a new, label-free, highly selective Surface Plasmon Resonance Imaging biosensor for the quantitative determination of matrix metalloproteinase-2. Matrix metalloproteinase-2 specific inhibitor, ARP 101, was used as the receptor, the main part of the biosensor, which bound the enzyme from the sample. The analytical response signal (linear part of the calibration curve) of the developed biosensor was in the range of 1.0–100.0 ng ml⁻¹. Its detection limit was 3.9 ng ml⁻¹, and the limit of quantification was 7.7 ng ml⁻¹. The selectivity, precision and accuracy of the new biosensor were acceptable. The biosensor was used for the quantitative determination of matrix metalloproteinase-2 in the blood plasma of healthy persons and in the plasma of burned children, with good results (good tolerance for potential interferents). Also, to validate the new biosensor, the measurements of plasma matrix metalloproteinase-2 concentration in the biological samples by Enzyme-Linked Immunosorbent Assay were conducted. It was found that the correlation between these two methods was good.